PureTech Health (PRTC) announced that Bharatt Chowrira has stepped down from his role as CEO and as a member of the board of directors. The board of directors has appointed Robert Lyne as interim CEO. Lyne joined PureTech as chief portfolio officer in January 2024 and is a leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience. He will continue to work closely with PureTech’s board and management team as the company delivers on its strategic objectives.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- PureTech Health says Raju Kucherlapati steps down as board chair
- PureTech Health founded entity Vor Bio enters license agreement with RemeGen
- Positive Outlook on PureTech Health Driven by Promising LYT-100 Clinical Trial Results and Strategic Developments
- PureTech Health presents deupirfenidone data at ATS conference